Rationale and design of the expanded combination of evolocumab plus empagliflozin in diabetes: EXCEED-BHS3 trial

Rationale and design of the expanded combination of evolocumab plus empagliflozin in diabetes: EXCEED-BHS3 trial

Background: Patients with type 2 diabetes mellitus (T2DM) remain at increased cardiovascular residual risk and endothelial dysfunction, even after optimizing metabolic control and treatment by sodium-glucose-2 transporter inhibitors (SGLT2-is). The present study was based on the hypothesis that prop...

Full description

Bibliographic Details
Main Authors: Ikaro Breder, Jessica Cunha Breder, Isabella Bonilha, Daniel B. Munhoz, Sheila T. Kimura Medorima, Daniela C. Oliveira, Helison R. do Carmo, Camila Moreira, Anatol Kontush, Francesca Zimetti, Ilaria Zanotti, Luiz Sergio F. Carvalho, Wilson Nadruz, Elza Muscelli, Thiago Quinaglia, Andrei C. Sposito
Format: Article
Language:English
Published: SAGE Publishing 2020-09-01
Series:Therapeutic Advances in Chronic Disease
Online Access:https://doi.org/10.1177/2040622320959248

Internet

https://doi.org/10.1177/2040622320959248

Similar Items